CAM
CADL icon

Close Asset Management’s Candel Therapeutics CADL Stock Holding History

Close Asset Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7K Hold
1,350
– – ﹤0.01% 237
2025
Q4 		$8K Hold
1,350
– – ﹤0.01% 234
2025
Q3 		$7K Hold
1,350
– – ﹤0.01% 237
2025
Q2 		$7K Buy
+1,350
New +$6.95K ﹤0.01% 225

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Close Asset Management's CADL Position: Q1 2026 in Review

Close Asset Management held its Candel Therapeutics (CADL) position steady in Q1 2026 at 1,350 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #237.

Close Asset Management first reported a position in CADL in Q2 2025 and has held it in 4 quarters since. The position peaked at $8K in Q4 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Close Asset Management held 1,350 shares of Candel Therapeutics worth $7K as of Q1 2026.
  • Close Asset Management left its Candel Therapeutics share count unchanged in Q1 2026.
  • Candel Therapeutics made up ﹤0.01% of Close Asset Management's portfolio in Q1 2026, its #237 holding.
  • Close Asset Management first reported a position in Candel Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Close Asset Management's Candel Therapeutics position peaked at $8K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Close Asset Management's 13F filing for Q1 2026, filed 12 May 2026.